-
I recently served as the moderator for MassBio’s forum on “Closing the Real-World Evidence Gap: Pragmatic Clinical Trials & Observational Studies.” This lively and informative discussion was led by a panel of industry leaders, which included Robert Califf, MD, MACC, Head of Medical Strategy and Policy, Verily Life Sciences and Google Health; Jane Liang White, ScD, Senior Director, Statistical Group Lead for Oncology/Hematology Franchise at Pfizer; and Rebecca Miksad, MD, MPH, Senior Medical Director of Flatiron Health.
-
Emerging biotech companies must master many challenges in bringing a product to market. Even the acronyms common to early development, like IND (Investigational New Drug Application), SAD (single ascending dose), and MAD (multiple ascending dose) imply that a company must know how their treatment impacts the body, how to analyze study results, and how to express their findings to regulatory authorities. The expertise of medical writers is valuable in helping an emerging biotech reach its drug development goals.
-
Last summer, PROMETRIKA partnered with Tutoring Plus of Cambridge, a local nonprofit that provides after-school tutoring and mentoring programs for Cambridge youths. Tutoring Plus was founded in 1964 and today serves about 175 students, with support of nearly 150 volunteers. Programs include one-on-one tutoring, as well as enrichment programs for topics ranging from writing to engineering. The programs are always free of cost to the students’ families.